Follow Us

News Details

Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1

About Outlook Therapeutics, Inc.
  • NASDAQ: $OTLK
  • Notified: $1.44
  • 08:05 EDT

Price Chart